Literature DB >> 19230048

Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.

Hong Cheng1, Fu-Lian Hu.   

Abstract

AIM: To compare the efficacy and side effect profiles of three furazolidone and amoxicillin-based quadruple rescue therapies for the eradication of Helicobacter pylori (H pylori).
METHODS: Patients who failed in the H pylori eradication therapy for at least one course were randomly allocated into three groups. Group A received rebaprazole 10 mg + amoxicillin 1 g + furazolidone 100 mg, and bismuth subcitrate 220 mg, twice daily for 1 wk; group B received the same regimen of group A but for 2 wk; and group C received the same regimen of group B, but furazolidone was replaced by furazolidone 100 mg three times daily. To record the side effect profiles at the end of the treatment, H pylori eradication was assessed with (13)C-urea breath test 4 wk after therapy.
RESULTS: Sixty patients were enrolled including 28 males, and 20 patients in each group. The average age of the patients was 49.2 years, ranging from 18 to 84 years. H pylori eradication rates with per-protocol analysis were 82%, 89% and 90% in the three groups, respectively. Side effects were found in 11 patients, including mild dizziness, nausea, diarrhea and increased bowel movement. None of the 11 patients needed treatment for their side effects.
CONCLUSION: One- or two-week furazolidone and amoxicillin-based quadruple rescue therapy with a low dose furazolidone (100 mg bid) for the eradication of H pylori is effective. Extending the antibiotic course to 14 d could improve the eradication rates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19230048      PMCID: PMC2653387          DOI: 10.3748/wjg.15.860

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

1.  Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).

Authors:  Gerhard Treiber; Joachim Wittig; Susanne Ammon; Siegfried Walker; Leen-Jan van Doorn; Ulrich Klotz
Journal:  Arch Intern Med       Date:  2002-01-28

2.  Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.

Authors:  H Fakheri; R Malekzadeh; S Merat; M Khatibian; A Fazel; B Z Alizadeh; S Massarrat
Journal:  Aliment Pharmacol Ther       Date:  2001-03       Impact factor: 8.171

3.  One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies.

Authors:  W M Wong; B C Y Wong; H Lu; Q Gu; Y Yin; W H Wang; F M Y Fung; K C Lai; H H X Xia; S D Xiao; S K Lam
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

4.  Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance.

Authors:  D H Kwon; M Lee; J J Kim; J G Kim; F A El-Zaatari; M S Osato; D Y Graham
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

5.  Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication.

Authors:  H Fakheri; S Merat; V Hosseini; R Malekzadeh
Journal:  Aliment Pharmacol Ther       Date:  2004-01-01       Impact factor: 8.171

6.  Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.

Authors:  G Treiber; S Ammon; P Malfertheiner; U Klotz
Journal:  Helicobacter       Date:  2002-08       Impact factor: 5.753

7.  Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.

Authors:  V Isakov; I Domareva; L Koudryavtseva; I Maev; Z Ganskaya
Journal:  Aliment Pharmacol Ther       Date:  2002-07       Impact factor: 8.171

8.  Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.

Authors:  Theodore Rokkas; Panos Sechopoulos; Ioannis Robotis; Georgios Margantinis; Dimitrios Pistiolas
Journal:  Am J Gastroenterol       Date:  2009-01       Impact factor: 10.864

9.  Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.

Authors:  Yuksel Gumurdulu; Ender Serin; Birol Ozer; Fazilet Kayaselcuk; Kursat Ozsahin; Arif Mansur Cosar; Murat Gursoy; Gurden Gur; Ugur Yilmaz; Sedat Boyacioglu
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

10.  Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.

Authors:  Engin Altintas; Orhan Sezgin; Oguz Ulu; Ozlem Aydin; Handan Camdeviren
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

View more
  15 in total

1.  In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori.

Authors:  Morris O Makobongo; Tchelet Kovachi; Hanan Gancz; Amram Mor; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

Review 2.  Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.

Authors:  Hong Lu; Wei Zhang; David Y Graham
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-10       Impact factor: 2.566

3.  Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.

Authors:  Yong Xie; Yin Zhu; Hong Zhou; Zhi-Fa Lu; Zhen Yang; Xu Shu; Xiao-Bai Guo; Hui-Zhen Fan; Jian-Hua Tang; Xue-Ping Zeng; Jian-Bo Wen; Xiao-Qing Li; Xing-Xing He; Jiu-Hong Ma; Dong-Sheng Liu; Cai-Bin Huang; Ning-Jian Xu; Nong-Rong Wang; Nong-Hua Lu
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 4.  Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.

Authors:  David Y Graham; Maria Pina Dore; Hong Lu
Journal:  Expert Rev Anti Infect Ther       Date:  2018-08-23       Impact factor: 5.091

Review 5.  Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.

Authors:  Angelo Zullo; Enzo Ierardi; Cesare Hassan; Vincenzo De Francesco
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

6.  Comparison of quadruple and triple Furazolidone containing regimens on eradication of helicobacter pylori.

Authors:  Marjan Mokhtare; Vahid Hosseini; Hafez Tirgar Fakheri; Iradj Maleki; Tarang Taghvaei; Seyed Mohammad Valizadeh; Hossein Sardarian; Shahram Agah; Alireza Khalilian
Journal:  Med J Islam Repub Iran       Date:  2015-04-06

7.  Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial.

Authors:  Aliakbar Hajaghamohammadi; Seyyed Hossein Safiabadi Tali; Rasoul Samimi; Sonia Oveisi; Amir Mohammad Kazemifar
Journal:  Glob J Health Sci       Date:  2014-08-31

8.  Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic.

Authors:  Muhammad Miftahussurur; Modesto Cruz; Dalla Doohan; Phawinee Subsomwong; José A Jiménez Abreu; Celso Hosking; Langgeng Agung Waskito; Yoshio Yamaoka
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240

9.  Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication.

Authors:  Ya-Wen Zhang; Wei-Ling Hu; Yuan Cai; Wen-Fang Zheng; Qin Du; John J Kim; John Y Kao; Ning Dai; Jian-Min Si
Journal:  World J Gastroenterol       Date:  2018-10-28       Impact factor: 5.742

10.  Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection.

Authors:  Airu Liu; Yuxin Wang; Yingxiao Song; Yiqi Du
Journal:  Saudi J Gastroenterol       Date:  2020 Mar-Apr       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.